Navigation Links
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Date:8/19/2007

Management to Make Two Presentations on the Topic of Drug Repurposing and

Indian Clinical Trial Strategy

MORRISTOWN, N.J., Aug. 16 /PRNewswire/ -- Vicus Therapeutics, Inc., an oncology-focused, clinical-stage biopharmaceutical company, announced today that Chief Executive Officer, John Maki, and Chief Scientific Officer, Frederic Young, Ph.D., will each present at the 234th American Chemical Society National Meeting on Sunday, August 19, 2007. The Meeting is being held at the Boston Convention & Exhibition Center in Boston, MA.

Dr. Young will present "Hypothesis-driven Drug Repurposing Based on a Novel Systems Biology Approach," including a discussion of Vicus' complexity theory-based drug repurposing approach in creating a pipeline of product candidates for the treatment of important unmet medical needs. The Company's approach can be applied to the discovery of product candidates for any indication, including cancer cachexia, a metabolic disorder, mucositis, a wound healing disorder, and cancer fatigue, a CNS disorder. The specific application of this method will be discussed in the context of the Company's lead compound, VT-122. Dr. Young's presentation is scheduled for 11:45 a.m.

Mr. Maki's presentation, entitled "Synergistic Advantages of Drug Repurposing and Clinical Trial Off-shoring in India", will include a discussion of the unique synergistic advantages of drug re-profiling and off- shoring, as well as an overview of the steps necessary to realize such advantages. Specifically, Mr. Maki will provide highlights from the Company's ongoing Phase 2 clinical trial of VT-122 for cancer cachexia, now being conducted in the U.S. and India. In addition, he will review recent changes by the Drug Controller General of India (DCGI, the Indian FDA-regulatory equivalent), Indian clinical research infrastructure, and the acceptance of Indian data by the U.S. Food & Drug Administration (FDA) that is currently driving the expl
'/>"/>

SOURCE Vicus Therapeutics

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today ... increased the purchase price of its previously announced "Modified ... to purchase, for cash, up to $65,000,000 aggregate principal ... 2.875% Senior Subordinated Convertible Notes due 2010. , The ...
... DIEGO, Nov. 9, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ... 30, 2009. , Arena reported a lower net loss allocable to ... or $0.38 per share, compared to a net loss allocable to ... or $0.76 per share, and a net loss allocable to common ...
Cached Medicine Technology:Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 2Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... team has created a new technology for modifying ... travel the body and selectively target cancer and ... devices that monitor and modify human physiology is ... no existing technology enabled bioengineers to build such ... respond in a customized fashion. , "The project ...
(Date:4/17/2014)... 2014) The cause of neuronal death in Parkinson,s ... that neurons may be mistaken for foreign invaders and ... the way autoimmune diseases like type I diabetes, celiac ... study was published April 16, 2014, in Nature ... controversial, idea in Parkinson,s disease; but if true, it ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on conservation ... today examining the current state of knowledge of the ... improved global surveillance strategies to combat the emergence of ... in West Africa that has claimed the lives of ... According to the World Health Organization (WHO), the ...
(Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... , Statement of Esta Soler, President, Family Violence Prevention Fund , ... today in Los Angeles in the domestic violence case involving Chris ... like this. Despite what was apparently an extremely violent assault, ... remained a felony, and that Mr. Brown pleaded guilty, taking responsibility ...
... , LOS ANGELES, June 22 Mission Viejo general surgeon ... the newly-elected Chair of the Mutual Protection Trust (MPT) Board ... the Cooperative of American Physicians, Inc. (CAP). Dr. Cobo,s election ... J. Michael Wormley, MD, a Glendora family practitioner who presided ...
... isolated a potent inhibitor of tumor metastasis made by tumor ... treatment. Their findings were published in the online Early Edition ... during the week of June 22. Metastasisthe ... one of the leading causes of death from cancer, and ...
... Tarzana Medical Center on Friday became the first. hospital in the ... Vision RFD - in this case to aid a surgeon in ... a small stroke. , , Zahi E. Nassoura, a board-certified ... saw in the crystal-clear image provided by the Ziehm Vision, approved ...
... misdiagnosis as the likely cause of apparent uptick in melanoma ... released study in the June 2009 British Journal of Dermatology ... United Kingdom has concluded that the much-hyped melanoma "epidemic" is ... attributed the increase in melanoma diagnoses to heightened sensitivity and ...
... The Department of Veterans Affairs (VA) has initiated a large, ... health issues that may affect Operation Enduring Freedom/Operation Iraqi Freedom ... time period. VA,s "National Health Study for a New ... to OEF/OIF and 30,000 comparison Veterans who were not deployed. ...
Cached Medicine News:Health News:Domestic Violence Expert Comments on Chris Brown Plea Deal 2Health News:Dr. Juan Carlos Cobo Newly-Elected Chair of the Mutual Protection Trust Board of Trustees 2Health News:Potent metastasis inhibitor identified 2Health News:Providence Tarzana Surgeon First in U.S. to Use New State-of-the-Art Imaging Tool 2Health News:New Study Says Purported Melanoma Epidemic is Vastly Overstated 2Health News:VA Launches 10-Year Health Study of 60,000 New Veterans 2
Test for prostatic acid phosphatase...
... you could imagine the ultimate OR, how ... efficiency? Would its control systems be intuitive? ... to quickly adapt to different tasks and ... longer need to imagine this environment. It's ...
... is the world's first Windows ... measuring system. It allows data sharing ... is compatible with Microsoft Office 2000. ... see on the large, sharp 14.1-inch ...
... T-series is a new top-line range of ... and Atrial Fibrillation (AF). Because the T-series ... AF, the treatment of AF is taken ... technology the heart rhythm is monitored continuously ...
Medicine Products: